Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Investment analysts at Wedbush boosted their Q3 2017 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report released on Wednesday. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.61) for the quarter, up from their prior forecast of ($0.63). Wedbush also issued estimates for Karyopharm Therapeutics’ Q4 2017 earnings at ($0.63) EPS, FY2017 earnings at ($2.59) EPS, Q1 2018 earnings at ($0.64) EPS, Q2 2018 earnings at ($0.59) EPS, Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.61) EPS, FY2018 earnings at ($2.44) EPS, FY2019 earnings at ($1.34) EPS and FY2021 earnings at $1.44 EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same quarter last year, the company earned ($0.84) earnings per share. The firm’s quarterly revenue was down 95.0% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: “Q3 2017 EPS Estimates for Karyopharm Therapeutics Inc. Lifted by Analyst (KPTI)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/25/q3-2017-eps-estimates-for-karyopharm-therapeutics-inc-lifted-by-analyst-kpti.html.

Other equities analysts have also recently issued research reports about the company. Canaccord Genuity set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 8th. Jefferies Group LLC reissued a “buy” rating and set a $19.00 price target (up previously from $16.00) on shares of Karyopharm Therapeutics in a report on Thursday, August 10th. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Thursday, July 6th. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Saturday, June 24th. Finally, BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $15.67.

Karyopharm Therapeutics (NASDAQ KPTI) opened at 10.83 on Monday. The firm’s market capitalization is $510.50 million. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The firm’s 50-day moving average price is $9.40 and its 200 day moving average price is $9.83.

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System grew its position in Karyopharm Therapeutics by 12.2% during the 2nd quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock worth $542,000 after acquiring an additional 6,500 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Karyopharm Therapeutics by 26.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after acquiring an additional 5,586 shares during the last quarter. State Street Corp grew its position in Karyopharm Therapeutics by 10.1% during the 2nd quarter. State Street Corp now owns 511,920 shares of the company’s stock worth $4,631,000 after acquiring an additional 47,127 shares during the last quarter. Palo Alto Investors LLC grew its position in Karyopharm Therapeutics by 1.8% during the 2nd quarter. Palo Alto Investors LLC now owns 3,467,575 shares of the company’s stock worth $31,382,000 after acquiring an additional 61,100 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth $136,000. Institutional investors and hedge funds own 58.97% of the company’s stock.

In related news, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the sale, the director now owns 2,882 shares in the company, valued at approximately $31,702. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 7,195 shares of company stock worth $76,950 in the last 90 days. 14.71% of the stock is currently owned by corporate insiders.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.